Investment Rating - The report indicates a positive outlook for the Poly-L-Lactic Acid (PLA) industry, with a projected compound annual growth rate (CAGR) of 20.4% from 2024 to 2030, suggesting strong investment potential in this sector [46][48]. Core Insights - The PLA market in China is still in its early stages, with a market size of approximately 1 billion yuan in 2021, expected to grow to 11 billion yuan by 2024 and reach 41 billion yuan by 2030 [48]. - The industry is characterized by a competitive landscape with 9 approved products and several others in development, indicating a diverse market with both domestic and imported brands [39]. - The rise of non-surgical aesthetic procedures has positioned PLA products like the "童颜针" (Youthful Needle) favorably, as they cater to a growing consumer base seeking natural anti-aging solutions [40][45]. Summary by Sections 1. Industry Overview - The PLA industry is primarily driven by the increasing demand for non-surgical aesthetic treatments, with a significant shift in consumer preferences towards natural and long-lasting results [40][45]. - The report highlights the importance of consumer education, as many potential users still confuse PLA products with traditional fillers, which may hinder market penetration [57][61]. 2. Market Dynamics - The PLA market is expected to benefit from a growing user base, particularly among the Z generation, who are becoming the main consumers of aesthetic procedures [84]. - The report notes that the market is currently dominated by domestic brands, with a focus on competitive pricing and innovative formulations [39]. 3. Competitive Landscape - The competitive landscape includes both domestic and imported brands, with a notable presence of 9 approved PLA products, each with distinct technical features and pricing strategies [33][39]. - The report outlines the pricing range for various products, indicating a clear segmentation in the market from high-end to more affordable options [34]. 4. Consumer Insights - Consumer motivations for seeking PLA treatments include personal satisfaction and social value, with safety and effectiveness being primary concerns [62][64]. - The report emphasizes the need for improved consumer understanding of PLA products, as many potential users are not fully aware of the benefits and mechanisms of action [57][61]. 5. Future Opportunities - The report identifies several growth opportunities, including the increasing penetration of aesthetic procedures among younger consumers and the potential for product innovation through technology [86][87]. - Regulatory changes are expected to enhance product quality and safety, further driving consumer trust and market growth [51][87].

Core Viewpoint - The dispute over the exclusive agency rights for the "童颜针" (AestheFill) between *ST Suwu and the medical beauty giant Aimeike has escalated, with *ST Suwu seeking arbitration and claiming significant financial losses due to alleged breaches of contract [2][5][6]. Group 1: Company Actions and Legal Proceedings - *ST Suwu's subsidiary, Datou Medical, has filed for arbitration with the Shenzhen International Arbitration Court regarding a breach of contract by Regen, seeking to confirm its exclusive agency rights for AestheFill and claiming preliminary damages of 1.6 billion yuan [2][6]. - The arbitration request was accepted by the Shenzhen International Arbitration Court on August 7, 2025 [5]. - *ST Suwu has publicly accused Aimeike of "capital bullying" and "serious damage to business ethics" in its defense [2][8]. Group 2: Financial Context and Company Performance - *ST Suwu is facing severe financial difficulties, including risks of forced delisting due to financial fraud allegations, with a reported inflated revenue of 1.77 billion yuan from 2020 to 2023 [3][9]. - Aimeike, which acquired 85% of Regen for $190 million in March 2025, is also experiencing declining financial performance, with revenue and net profit growth rates dropping to single digits in 2024 [3][12]. - Aimeike's market capitalization has decreased from over 180 billion yuan at its peak to approximately 60 billion yuan, reflecting a loss of over 120 billion yuan [4][14]. Group 3: Market Implications and Future Outlook - The ongoing dispute over the AestheFill agency rights is critical for both companies, as AestheFill is seen as a potential growth driver for Aimeike amidst its declining performance [10][11]. - The market has reacted negatively to the news, with *ST Suwu's stock price experiencing consecutive trading halts following the announcement of the termination of its agency rights [8]. - The outcome of the arbitration and the future of the AestheFill product in the Chinese market remain uncertain, with significant implications for both companies and their stakeholders [4][15].

爱美客对*ST苏吴方面提起仲裁并不意外，但目前还未正式收 到仲裁机构的口头或书面通知。 作者：刘晓诺 封图：图虫创意 自称"已陷入生死存亡的困境"的*ST苏吴（600200.SH），把AestheFill"童颜针"代理权之争推进 到了法律层面。 8月11日晚，*ST苏吴发布公告，其控股孙公司达透医疗器械（上海）有限公司（下称"达透公 司"）已向深圳国际仲裁院申请仲裁，并已于8月7日获受理立案。仲裁的另一方当事人，便是爱美 客（300896.SZ）间接控股的韩国公司REGEN Biotech,Inc.（下称"REGEN"）。 关于上述仲裁请求，爱美客相关负责人表示："在我们看来，是达透公司有违约行为在先，而且他 们的行为在经济和品牌商誉方面，对我们都有影响。我们也会根据情况采取法律手段，维护我们的 正当权益。" REGEN公司与达透公司的代理权纠纷自2025年7月开始发酵。 "童颜针"AestheFill本是韩国REGEN公司的产品，达透公司具有该产品在中国大陆地区的独家代理 权。2021年底，*ST苏吴花了1.66亿元间接控股了达透公司，并将AestheFill打造为其核心产品。 *ST苏吴称，据不完全统计， ...

Core Viewpoint - The medical beauty industry is experiencing a transition from chaotic growth to regulated development, with increasing scrutiny on issues such as false advertising, illegal operations, and unlicensed medical practices [1] Group 1: Industry Challenges - The medical beauty sector is facing rampant issues including misleading promotions and illegal injections, which have been highlighted in various media reports [1] - Recent investigations revealed that some legitimate medical beauty institutions are involved in deceptive practices, including unauthorized injections and the use of smuggled products [1] Group 2: Regulatory Measures - Guangdong province is implementing a multi-faceted approach to address these issues, involving collaboration among health, drug supervision, police, and market regulation departments [2] - New regulations have been introduced, such as the prohibition of non-medically necessary cosmetic procedures for minors and the requirement for public institutions to sell medical supplies at zero markup [2][3] - A comprehensive regulatory network has been established, with a focus on dynamic policy improvements based on emerging issues [3] Group 3: Enforcement Actions - In 2022, a special campaign led to the closure of 217 illegal medical beauty establishments and fines totaling 38.6 million yuan [3] - Ongoing joint enforcement actions are transforming regulatory measures from theoretical frameworks into practical applications, ensuring compliance and safety [5][6] - The introduction of a "double review system" for injectable medical devices aims to close loopholes in online sales [3] Group 4: Future Outlook - The ongoing transformation in the medical beauty industry in Guangdong is expected to lead to a more regulated and orderly market, enhancing public safety and trust [6] - The collaborative efforts among various regulatory bodies are designed to create a robust framework for the sustainable development of the medical beauty sector [6]

21世纪经济报道记者唐唯珂 广州报道 医美行业热度持续攀升，但在快速发展中，虚假宣传、违规操作、非法行医等乱象频发，行业正经历从 野蛮生长到规范发展的阵痛。 8月3日晚，央视财经视频号发布医美相关新闻，其中有3条系财经调查类，涉及部分正规医美机构蒙骗 诱导，违规注射、无资质非法注射走私针剂、小红书成各类针剂违规代打接单平台等。 这并非医美乱象首次被聚焦。此前，医美就已经在315晚会被多次被点名，央视于7月也曾曝光"医美速 成班""量产"非法行医者的问题。而此次对注射类医美乱象的集中曝光，既是对医美乱象严打的体现， 又再一次将公众视线聚焦于医美安全与合规的核心议题之上。 针对现状，作为医美消费大省的广东，多部门协同联动，构建起政策与执法并重的治理体系，全力守护 群众"求美之路"的安全。 多管齐下 广东省以高压态势治理乱象，卫健、药监、公安、市场监管等多部门协同联动，从制度完善、执法强化 到模式创新，一步步筑牢行业规范发展的防线，全力守护群众的身体健康和生命安全。 治理的第一步，是搭建全链条的制度监管网络。广东对医美行业的治理，始终以"最新问题导向"动态完 善政策，2025年以来多项新规密集出台，成为监管升级的重 ...

Summary of Conference Call Notes Industry or Company Involved - Miniso (名创优品) - Top Toy - Yonghui Supermarket (永辉超市) - Baijiu Industry (白酒行业) - Express Delivery Industry (快递行业) - Weixing Precision (帏翔精密) - TCL Electronics (TCL 电子) - Aimeike (爱美客) Key Points and Arguments Miniso Performance and Strategy - Miniso achieved revenue of 400 million in 2024, a year-on-year increase of 23% and a net profit of 2.6 billion, up 16% [2] - The company opened 460 new stores in China, totaling 4,386 stores [2] - The SKU count increased to 12,600 with a monthly launch rate of 1,180 new products [2] - In overseas markets, particularly North America, 265 new stores were opened, with overseas GMV growth exceeding 50% and agency market growth at 17% [4] Top Toy Development - Top Toy opened 128 new stores last year, doubling its store count and achieving profitability with a pre-tax profit margin exceeding 9% [2][5] Yonghui Supermarket Acquisition - The acquisition of Yonghui Supermarket was completed in Q1, with expectations for it to break even this year, limiting its drag on Miniso [6] Baijiu Industry Trends - The baijiu industry is expected to see an upward turning point, with inventory decreasing year-on-year and improved demand during the Spring Festival [7] - High-end liquor demand remains stable, while mid-to-low price segments face challenges [7] Express Delivery Industry Insights - In early March, express delivery volume growth remained at 20%-21%, higher than expected [8] - A shift in the industry from peak to off-peak season is anticipated, with revenue growth expected to approach 15% [8] Weixing Precision Financials - Weixing Precision reported a net profit of 10.15 billion in 2024, a 12.7% year-on-year increase, meeting expectations [9] TCL Electronics Performance - TCL Electronics reported revenue of 99.32 billion HKD in 2024, a 25.7% increase, and a net profit of 1.61 billion HKD, up 100.1% [13] - The company expects a dividend payout ratio of 50% [13] - TV sales in China grew by 5.8%, while overseas sales increased by 17.6% [13] Aimeike's Financial Performance - Aimeike's revenue and net profit growth were approximately 5% in 2024, but Q4 saw a decline in revenue by 7% and net profit by 15% [17] - The company plans to focus on internal growth and external acquisitions, with several new products expected to launch in 2025 [18][20] Future Outlook for Aimeike - Aimeike's revenue and profit growth is projected to be around 11% in 2025, with potential acceleration in 2026 and 2027 due to new product launches and acquisitions [20] Other Important but Possibly Overlooked Content - The express delivery industry is facing a transition period, and companies like Zhongtong Express are setting ambitious growth targets of 20%-24% for parcel volume [10] - Yunda is under investigation by the National Postal Administration, which may affect its business relationships with major clients [11] - SF Express's strategic investment in Dekun Logistics aims to enhance cost efficiency through business collaboration [12] - TCL's other display and internet business segments showed steady growth, with significant contributions from innovative business areas [14][15]

Investment Rating - The report maintains a "Buy" rating for the cosmetics and medical beauty sector, particularly highlighting companies like Shiseido and Up Beauty for their strong performance and growth potential [12][14]. Core Insights - The cosmetics and medical beauty sector underperformed the market during the week of August 1 to August 8, 2025, with the Shenwan Beauty Care Index growing by 1.7%, which is lower than the overall market performance [5][6]. - There is a notable divergence in the performance of domestic beauty brands in July, with strong growth observed in skincare brands like Han Shu and Marubi, while color cosmetics lagged due to weather and promotional timing [11][12]. - Up Beauty's H1 2025 performance exceeded expectations, with revenue projected between 4.09 to 4.11 billion yuan, reflecting a year-on-year growth of 16.8% to 17.3% [12][13]. Summary by Sections Industry Performance - The Shenwan Cosmetics Index increased by 1.3%, underperforming the Shenwan A Index by 0.6 percentage points, while the Shenwan Personal Care Index rose by 4.2%, outperforming the Shenwan A Index by 2.3 percentage points [5][6]. - The top-performing stocks in the sector included Up Beauty (+18.4%), Reliable Shares (+13.7%), and Lafang Home (+11.3%) [7]. Key Company Updates - Up Beauty's H1 2025 earnings report indicated a significant profit increase, with net profit margins improving due to optimized channel structures and a higher proportion of high-margin brands [12][13]. - Shiseido reported a 7.6% decline in sales for H1 2025, marking the largest drop in five years, with a notable decrease in the Chinese market [24]. E-commerce Insights - In July 2025, domestic beauty brands showed varied performance on major e-commerce platforms, with Han Shu achieving a 58% increase in GMV on Douyin, while color cosmetics faced challenges [20][21]. - The overall retail sales of cosmetics in June 2025 saw a decline of 2.3%, attributed to the pre-promotion of the 618 shopping festival [21][24]. Market Trends - The report highlights a shift in market dynamics, with domestic brands gaining market share against international competitors, particularly in the skincare segment [34][35]. - The Chinese skincare market is projected to reach 271.2 billion yuan in 2024, despite a 3.7% decline in growth [34][35].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the emergence of differentiated membership stores, such as the WS Jiangtun membership store launched by Wushang Group in Wuhan, which focuses on unique products and services [5][24] - The report emphasizes the importance of emotional consumption themes and recommends high-quality companies in sectors like gold jewelry, offline retail, cosmetics, and medical aesthetics [8][29] Summary by Sections Retail Market Review - The retail industry index reported a decline of 0.38% for the week of August 4 to August 8, 2025, underperforming the Shanghai Composite Index, which increased by 2.11% [14][21] - The jewelry sector showed the highest growth among retail sub-sectors, with a weekly increase of 6.07% and a year-to-date increase of 32.99% [16][19] Retail Insights - Wushang Group's WS Jiangtun membership store adopts a "paid membership + selected products" model, aiming to provide a differentiated shopping experience [5][24] - The store features a dual membership structure with basic and diamond tiers, enhancing customer engagement and loyalty [25] Investment Recommendations - Focus on gold jewelry brands with differentiated product offerings and consumer insights, recommending companies like Laopu Gold and Chaohongji [8][29] - Highlight the potential of offline retail companies that adapt to consumer trends, recommending Yonghui Supermarket and Aiyingshi [8][29] - Emphasize the growth of domestic cosmetics brands, recommending companies like Maogeping and Pola [8][29] - Suggest investment in medical aesthetics firms with differentiated product lines, recommending Aimeike and Kedi-B [8][29] Company Performance Highlights - Laopu Gold achieved a revenue of 8.506 billion yuan in FY2024, with a net profit increase of 253.9% [31][36] - Yonghui Supermarket reported a revenue of 17.479 billion yuan in Q1 2025, with a significant decline in net profit [31] - Chaohongji's Q1 2025 revenue increased by 25.4%, driven by its focus on fashion jewelry [43]

Group 1 - The competition theme is "Technology Leads Aesthetic Surgery, Innovation Drives The Future" [4] - The event is organized by Beijing Ba Da Chu Plastic Surgery Medical Technology Group Co., Ltd. and Zhongguancun Medical Device Park Co., Ltd. [4] - The competition aims to promote innovative projects in the field of aesthetic surgery and medical beauty [4][5] Group 2 - The competition structure includes various regional competitions, each led by an academic leader who coordinates resources and manages the event [7] - The competition is divided into several regional areas, including East, South, West, North, and Central regions, covering multiple provinces [8] Group 3 - Participants must be from medical institutions, universities, or innovative enterprises in the aesthetic field, with a focus on projects related to plastic surgery, medical beauty, and related technologies [22] - The evaluation committee consists of clinical experts and transformation experts, with a total of 10-15 judges [22] Group 4 - The evaluation criteria include innovation, technical feasibility, market potential, team capability, and transformation potential, with specific weightings assigned to each dimension [23] - Awards include first, second, and third prizes, along with excellence awards, with monetary rewards and service packages for winners [25] Group 5 - The competition timeline includes a registration phase from June 10 to August 31, 2025, followed by preliminary evaluations and finals in September and October [25][26] - The final event will feature a forum and project roadshow, culminating in the announcement of winners [26]

Core Viewpoint - Huaxi Bio, once a star in the medical beauty sector, has seen a significant decline in stock price and market value since its peak in 2021, prompting the controlling shareholder to announce a share buyback plan for the first time since its IPO in 2019 [3][5][7]. Group 1: Stock Performance and Market Sentiment - Huaxi Bio's stock price peaked at approximately 312.99 yuan, but has since dropped about 82%, with a market value evaporating over 100 billion yuan [3][5]. - The controlling shareholder plans to buy back shares worth 200 million to 300 million yuan, with a maximum purchase price of 70 yuan per share, which is relatively small compared to the current market value of 25.3 billion yuan [5][7]. - Following the announcement, the stock experienced a brief increase of about 3% but closed with only a 0.71% gain, indicating limited market impact [7]. Group 2: Institutional Investor Behavior - Institutional funds have been steadily exiting Huaxi Bio, with the number of funds holding shares dropping from 421 at the end of 2022 to 158 by the end of 2024, and the total shareholding value decreasing significantly [10][12]. - The Hong Kong Central Clearing and Settlement System also reported a reduction in holdings, with shares decreasing from 816.1 million to 448.7 million over six months [12]. - The second-largest shareholder, a private equity fund under China Life, has also been reducing its stake, indicating a broader trend of capital flight from the company [12][16]. Group 3: Financial Performance and Strategic Challenges - Huaxi Bio's revenue and profit growth has sharply declined, with 2023 showing a revenue drop of 4.45% and a net profit decrease of 38.97%, followed by an even worse performance in 2024 [20][22]. - The company's strategic shift towards consumer products has not yielded the expected results, leading to increased marketing expenses and a decline in overall profitability [25][26]. - The competitive landscape has intensified, with rivals gaining market share in both B-end and C-end markets, eroding Huaxi Bio's previous advantages [26][27]. Group 4: Management Issues and Allegations - Frequent changes in the management team have raised concerns about internal stability, with ten executive changes reported in 2024 alone [29]. - Allegations of financial misconduct have surfaced, with a former executive claiming to have evidence of financial fraud, although the company has denied these claims [33][35]. - Previous reports of shareholder grievances regarding the treatment of employee stock options have also surfaced, further complicating the company's reputation [35].